Royalty Pharma Plc (RPRX)
64.76
+0.90
(+1.41%)
USD |
NASDAQ |
Oct 26, 16:00
64.88
+0.12
(+0.19%)
After-Hours: 19:16
Royalty Pharma Enterprise Value : 39.54B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 39.54B |
| October 22, 2026 | 39.49B |
| October 21, 2026 | 38.78B |
| October 20, 2026 | 38.83B |
| October 19, 2026 | 37.94B |
| October 16, 2026 | 38.25B |
| October 15, 2026 | 37.65B |
| October 14, 2026 | 37.37B |
| October 13, 2026 | 36.29B |
| October 12, 2026 | 36.83B |
| October 09, 2026 | 36.45B |
| October 08, 2026 | 36.13B |
| October 07, 2026 | 36.38B |
| October 06, 2026 | 36.24B |
| October 05, 2026 | 36.33B |
| October 02, 2026 | 36.56B |
| October 01, 2026 | 36.77B |
| September 30, 2026 | 37.09B |
| September 29, 2026 | 37.03B |
| September 28, 2026 | 37.10B |
| September 25, 2026 | 37.02B |
| September 24, 2026 | 37.06B |
| September 23, 2026 | 36.78B |
| September 22, 2026 | 37.16B |
| September 21, 2026 | 37.13B |
| Date | Value |
|---|---|
| September 18, 2026 | 37.11B |
| September 17, 2026 | 37.35B |
| September 16, 2026 | 37.14B |
| September 15, 2026 | 37.14B |
| September 14, 2026 | 37.40B |
| September 11, 2026 | 37.20B |
| September 10, 2026 | 37.27B |
| September 09, 2026 | 38.09B |
| September 08, 2026 | 38.09B |
| September 04, 2026 | 39.59B |
| September 03, 2026 | 39.55B |
| September 02, 2026 | 39.21B |
| September 01, 2026 | 38.86B |
| August 31, 2026 | 38.45B |
| August 28, 2026 | 38.20B |
| August 27, 2026 | 38.68B |
| August 26, 2026 | 38.62B |
| August 25, 2026 | 38.75B |
| August 24, 2026 | 38.42B |
| August 21, 2026 | 38.41B |
| August 20, 2026 | 38.08B |
| August 19, 2026 | 38.59B |
| August 18, 2026 | 37.68B |
| August 17, 2026 | 37.58B |
| August 14, 2026 | 37.20B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Merck & Co., Inc. | 405.39B |
| Johnson & Johnson | 662.44B |
| ANI Pharmaceuticals, Inc. | 1.903B |
| Corcept Therapeutics, Inc. | 8.967B |
| Veru, Inc. | 15.08M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 81.49M |
| Revenue (Quarterly) | 674.14M |
| Total Expenses (Quarterly) | 656.26M |
| EPS Diluted (Quarterly) | 0.04 |
| Gross Profit Margin (Quarterly) | 99.81% |
| Profit Margin (Quarterly) | 12.09% |
| Earnings Yield | 2.90% |
| Operating Earnings Yield | 4.64% |
| Normalized Earnings Yield | 2.727 |